These results indicated that CT053 suppressed tumor growth in the CDX and PDX models with high MET expression in a dose-dependent manner, and the attenuation of tumor growth by CT053 most likely occurs due to its inhibition of MET signaling activity. Here, MET is linked to neoplasm.